Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter and full year 2020 financial results on March 24, 2021, before U.S. markets open. A conference call will follow at 8:00 a.m. EST to discuss the results and business updates. Interested parties can access the call via phone or through a live webcast on the company's investor site. Cerevel is focused on neuroscience diseases, with a pipeline of five clinical-stage therapies targeting conditions such as Parkinson's and schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) will participate in the Cowen 41st Annual Health Care Conference on March 3, 2021. The presentation is scheduled for 11:00 a.m. EST and will be available via live webcast on their investor relations website. Cerevel specializes in neuroscience diseases and is advancing multiple clinical-stage therapies for conditions like Parkinson’s, epilepsy, and schizophrenia.
The company emphasizes its unique approach combining neurocircuitry knowledge with receptor selectivity.
Cerevel Therapeutics has announced that darigabat is now the international nonproprietary name for CVL-865, a Phase 2 GABA Positive Allosteric Modulator. The company is hosting a live R&D event to detail its ongoing Phase 2 trials for darigabat in drug-resistant focal epilepsy and acute anxiety. Cerevel plans to file U.S. IND applications in 2021 for its PDE4B and Kappa Opioid Receptor Agonist preclinical programs. Darigabat has been well-tolerated in previous trials, showing effectiveness in epilepsy treatment.
Cerevel Therapeutics has appointed Deval Patrick and Deborah Baron as independent members of its Board of Directors. Patrick, a former Massachusetts governor, brings expertise in the life sciences sector, while Baron serves as senior vice president at Pfizer, leading global business development. CEO Tony Coles expressed optimism about their contributions to Cerevel's goal of becoming a premier neuroscience company. Cerevel focuses on developing innovative treatments for conditions like Parkinson's disease and schizophrenia, boasting a diverse pipeline of clinical-stage therapies.
Cerevel Therapeutics will host a virtual R&D event on January 28, from 9:00 to 11:00 a.m. EST, focusing on CVL-865, a Phase 2 GABA positive allosteric modulator. The presentation will include insights into CVL-865 and preclinical programs.
CVL-865 is currently under investigation in two clinical trials: the REALIZE trial for drug-resistant focal onset seizures, with results expected in 2022, and a Phase 1 trial for acute anxiety, with results anticipated in 2021. The webcast will be available for replay for 90 days.
Cerevel Therapeutics (Nasdaq: CERE) has appointed Dr. Ruth McKernan as an independent board member. A seasoned expert in neuroscience, Dr. McKernan has over 25 years of experience in the pharmaceutical industry, including leadership roles at Pfizer and Merck. She currently works with SV Health Investors, focusing on neurodegenerative disorders. CEO Tony Coles believes her expertise will enhance Cerevel's innovation in therapies for diseases like schizophrenia and Parkinson's. Cerevel aims to establish itself as a premier neuroscience company.
Cerevel Therapeutics (Nasdaq: CERE) will host a live webcast on December 14 from 11:00 a.m. to noon EST, providing a corporate overview and a moderated Q&A session. Presenters include Tony Coles, Ray Sanchez, and John Renger, alongside Kathy Yi as part of the Q&A. Access to the live webcast will be available via the company’s investor relations website, with a replay for 90 days. Cerevel focuses on treating neuroscience diseases and has a pipeline of five clinical-stage therapies for conditions like schizophrenia and Parkinson’s disease.
Cerevel Therapeutics (Nasdaq: CERE) announced that its Chairperson and CEO, Tony Coles, M.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference. The event is scheduled for December 2, 2020, at 3:05 p.m. EST. Interested parties can access the live webcast through the investor relations section of the Cerevel website, where a replay will be available for about 90 days. Cerevel focuses on treating neuroscience diseases with a diversified pipeline of therapies targeting conditions like schizophrenia and epilepsy.
Cerevel Therapeutics debuted on Nasdaq under the symbol CERE after a significant business combination with ARYA Sciences Acquisition Corp II, raising net proceeds of approximately $440 million. The company initiated clinical trials for its leading programs targeting schizophrenia, epilepsy, anxiety, and Parkinson's disease. Financial results for Q3 2020 revealed a net loss of $39 million, versus $36 million in Q3 2019, with cash reserves expected to fund operations into 2023. R&D expenses increased to $24 million from $17 million year-over-year.
Cerevel Therapeutics (NASDAQ:CERE) announced participation in three virtual investor conferences in November 2020. The events include:
- Guggenheim Healthcare Talks on November 16, focusing on neuro/immunology.
- Stifel 2020 Virtual Healthcare Conference on November 17, featuring a fireside chat at 10:00 a.m. EST.
- Jefferies Virtual London Healthcare Conference on November 18-19, with a chat at 10:50 a.m. EST on November 18.
Live webcasts will be available on the company's investor relations page.
